Cyteir Therapeutics Stock Price To Sales
Cyteir Therapeutics fundamentals help investors to digest information that contributes to Cyteir Therapeutics' financial success or failures. It also enables traders to predict the movement of Cyteir Stock. The fundamental analysis module provides a way to measure Cyteir Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Cyteir Therapeutics stock.
Cyteir |
Cyteir Therapeutics Company Price To Sales Analysis
Cyteir Therapeutics' Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
CompetitionBased on the latest financial disclosure, Cyteir Therapeutics has a Price To Sales of 0.0 times. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The price to sales for all United States stocks is 100.0% higher than that of the company.
Cyteir Price To Sales Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cyteir Therapeutics' direct or indirect competition against its Price To Sales to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Cyteir Therapeutics could also be used in its relative valuation, which is a method of valuing Cyteir Therapeutics by comparing valuation metrics of similar companies.Cyteir Therapeutics is currently under evaluation in price to sales category among its peers.
Cyteir Fundamentals
| Return On Equity | -0.24 | |||
| Return On Asset | -0.14 | |||
| Current Valuation | (20.89 M) | |||
| Shares Outstanding | 36 M | |||
| Shares Owned By Insiders | 6.63 % | |||
| Shares Owned By Institutions | 76.83 % | |||
| Number Of Shares Shorted | 319.73 K | |||
| Price To Earning | 0.36 X | |||
| Price To Book | 0.87 X | |||
| Gross Profit | (16.59 M) | |||
| EBITDA | (33.41 M) | |||
| Net Income | (33.22 M) | |||
| Cash And Equivalents | 166.4 M | |||
| Cash Per Share | 4.71 X | |||
| Total Debt | 889 K | |||
| Debt To Equity | 0.02 % | |||
| Current Ratio | 19.95 X | |||
| Book Value Per Share | 3.47 X | |||
| Cash Flow From Operations | (25.79 M) | |||
| Short Ratio | 3.07 X | |||
| Earnings Per Share | (0.93) X | |||
| Price To Earnings To Growth | (0.03) X | |||
| Target Price | 3.0 | |||
| Number Of Employees | 46 | |||
| Beta | 0.096 | |||
| Market Capitalization | 108.71 M | |||
| Total Asset | 153.23 M | |||
| Retained Earnings | (138.11 M) | |||
| Working Capital | 143.89 M | |||
| Current Asset | 834.8 M | |||
| Current Liabilities | 366.9 M | |||
| Net Asset | 153.23 M |
Thematic Opportunities
Explore Investment Opportunities
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Other Consideration for investing in Cyteir Stock
If you are still planning to invest in Cyteir Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Cyteir Therapeutics' history and understand the potential risks before investing.
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities |